Abstract Submission Guidelines

General Guidelines

Submission of an abstract acknowledges your consent to the following:
• If accepted, your abstract may be published in the Congress program, as well as in the Haemophilia journal supplement.
• If accepted as an oral presentation, your PowerPoint presentation may be posted on the WFH website, on-site and post conference.
• If accepted as a poster presentation, you will display your poster at the Congress.

Abstract Submission and Review Timeline

The deadline for abstract submission is February 25, 2019 at 11:59 pm EST. The results of the peer review will be announced on the week of March 18, 2019. The submitter will be notified by email.

Author Information

During the abstract submission process, you will be asked to enter author information and affiliations. Please list the authors in your preferred citation order. If you are submitting supporting graphs or tables, please do NOT include the author list in the Word document, as we operate by blind review.

Presenting Author Registration

A Presenting Author must be designated to attend the congress and present the submitted abstract, should it be accepted. Presenting Authors (for both orals and posters) must register to attend MSK 2019. If the Presenting Author is not registered by the registration deadline of Friday, March 29, 2019, the abstract will not be included in the final program.

Disclosure of potential Conflict of Interest

If an author or immediate family member has had a substantial personal financial relationship relating to the support of the abstract, this relationship must be disclosed. Such relationships include salaries, ownership, equity positions, stock options, royalties, consulting fees and honoraria for speaking, material support and other financial arrangements. During the abstract submission process you will be asked to disclose any potential conflicts of interest.

Submission Instructions

Language of Abstract

Your abstract must be submitted in English.

Abstract Categories

• Orthopedics (Surgical)
• Physiotherapy (Non-Surgical)

Number of Submissions

Each author may present a maximum of two abstracts at the Congress. The number of submissions is, however, unlimited. Should an author have more than two abstracts accepted a co-author must be named as presenting author for the additional abstracts.

Presentation Format

During the abstract submission, you will be asked your preferred presentation format:
• Free paper (oral presentation)
• Poster
Authors selecting free paper may be offered a poster presentation if not selected for an oral.

Title and Abstract Length

Abstracts should be no more than 350 words in length; the title is not included in the word count. Please use Title Case (capital letters to start the principal words) for your abstract title instead of all CAPITAL or all small letters. Please note that abstracts which exceed the word limit may be excluded from the program. Data tables will count as 50 words towards the 350 word limit.

Submission Format

Your abstract requires a minimum of 4 sections (e.g., Introduction and Objectives/ Material and Methods/ Results/ Conclusions). You will be able to list your own headings.
On the submission form, copy/paste your abstract into the respective sections. A separate field will be available to list the title.
Should you have supporting tables or graphs, you will have the option to upload them in a Word document format.

Abstract Sample

Predictors of response to combination therapy with recombinant factor VIIa and factor VIII in patients with hemophilia A and high titer inhibitors

Introduction and Objectives:
Although the use of bypassing agents has significantly improved the treatment of hemophilia A patients who develop inhibitors, some patients, for unknown reasons, have a poor hemostatic response to bypass therapy. Improved treatment options for patients with inhibitors are needed. Studies from our laboratory and others have shown that even small amount of factor VIII (fVIII) activity can vastly improve the thrombin generation (TG) capability of recombinant factor VIIa (fVIIa) in patients with hemophilia A and inhibitors.

Materials and Methods:
Plasma from patients with congenital hemophilia A and high titer inhibitors was available from our IRB approved inhibitor bank. Each plasma sample was evaluated for response to 2 U/ml fVIII (~100 U/kg dosing) with and without 2.25 mcg/ml rfVIIa in a thrombin generation assay. Residual fVIII activity at 15 minutes after addition of 2 U/ml fVIII was measured using a one-stage coagulation assay.

15 different patients with inhibitor titers ranging from 5.2-109 BU/ml were tested. In the 10 patients with inhibitor titers of 5.2-28 BU/ml only 1 patient with a titer of 20 BU/ml did not respond to fVIII supplementation. In the 5 patients with inhibitor titers >42 BU/ml, there was no increase in TG. A second specimen was available for 4 patients. All 3 patients who had increased TG in the presence of fVIII continued to have increased TG in the second specimen despite up to a 2-fold difference in inhibitor titer. A subset of 10 patients also had residual fVIII activity testing. In this group residual fVIII activity strongly correlated with peak TG (r2 = 0.86, p>0.001) and also correlated with ETP (r2 = 0.54, p=0.04).

The majority of patients with hemophilia A and high titer inhibitors have improved TG with combined use of fVIII and rfVIIa over rfVIIa alone. Residual fVIII activity at 15 minutes was a predictor of both peak thrombin generation and ETP. An inhibitor titer above 42 BU/ml was associated with no response.